Lung cancer: open trials in Portugal

42 open trials have a site in Portugal. Registry data; only the trial team decides who can take part.

NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Trial Treatment · Phase 3 · Amgen
Centro Hospitalar Universitario De Lisboa Norte E.P.E., Lisbon · Hospital Cuf Tejo S.A., Lisbon · Champalimaud Clinical Centre, Lisbon · Hospital da Luz, S.A, Lisbon · Hospital CUF Porto S.A., Porto · Unidade Local De Saude De Matosinhos E.P.E., Senhora Da Hora
Registry updated 2026-11-06
NCT06793215
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Hoffmann-La Roche
Hospital de Braga, Braga · Hospital Beatriz Ângelo, Loures · IPO do Porto, Porto · CHVNG/E_Unidade 1, Vila Nova de Gaia
Registry updated 2026-11-05
NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
Centro Hospitalar E Universitărio de Coimbra E.P.E., Coimbra · Centro Hospitalar Universitario De Lisboa Norte E.P.E., Lisbon · Hospital da Luz, S.A, Lisbon · Champalimaud Clinical Centre, Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto · Hospital CUF Porto S.A., Porto · Unidade Local De Saude De Santo Antonio E.P.E., Porto
Registry updated 2026-11-04
NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 3 · Bayer
Unidade Local de Saúde de Coimbra, E.P.E., Coimbra · Unidade Local De Saude De Santa Maria E.P.E., Lisbon · Champalimaud Clinical Centre, Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto · Unidade Local De Saude De Matosinhos E.P.E., Senhora Da Hora
Registry updated 2026-11-04
NCT06890598
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
Centro Hospitalar e Universitario de Coimbra, Coimbra · Hospital da Luz Lisboa, Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto · Hospital CUF Porto, Porto
Registry updated 2026-11-04
NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Servico de Saude da Regiao Autonoma Da Madeira EPERAM, Funchal · Unidade Local De Saude De Santa Maria E.P.E., Lisbon · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Hospital Cuf Tejo S.A., Lisbon · Unidade Local De Saude De Matosinhos E.P.E., Matosinhos · Unidade Local de Saúde de Gaia/Espinho, E. P. E, Vila Nova de Gaia
Registry updated 2026-11-03
NCT06667076
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
CCAB Centro Clinico Academico Braga Associacao, Braga · Unidade Local De Saude Do Alto Ave E.P.E., Guimaraes · Hospital Cuf Tejo S.A., Lisbon · Unidade Local De Saude De Loures-Odivelas EPE, Loures · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto · Unidade Local de Saúde de Gaia/Espinho, E. P. E, Vila Nova de Gaia
Registry updated 2026-11-03
NCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Trial Treatment · Phase 3 · Boehringer Ingelheim
Hospital da Luz, S.A, Lisbon · Hospital Cuf Tejo S.A., Lisbon · Hospital CUF Porto S.A., Porto · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto
Registry updated 2026-11-02
NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.
Unidade Local de Saúde de Coimbra, E.P.E., Coimbra · Unidade Local De Saude Do Alto Ave E.P.E., Guimaraes · Hospital Cuf Tejo S.A., Lisbon · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Hospital Cuf Descobertas S.A., Lisbon · Unidade Local De Saude De Santo Antonio E.P.E., Porto · Hospital CUF Porto S.A., Porto
Registry updated 2026-10-30
NCT04928846
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · AbbVie
Champalimaud Clinical Centre, Lisbon · Hospital CUF Porto S.A., Porto · University Of Porto, Porto · Centro Hospitalar Universitario Do Porto E.P.E., Porto · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto
Registry updated 2026-10-29
NCT04886804
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Trial Treatment · Phase 1 · Boehringer Ingelheim
Hospital Cuf Descobertas S.A., Lisbon · Hospital CUF Porto S.A., Porto
Registry updated 2026-10-28
NCT07109726
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Trial Treatment · Phase 1/2 · Terremoto Biosciences Inc.
Centro Clínico Académico de Braga, Braga · START Lisboa, Lisbon
Registry updated 2026-10-28
NCT07472517
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Trial Treatment · Phase 3 · Boehringer Ingelheim
CCAB Centro Clinico Academico Braga Associacao, Braga · Unidade Local de Saúde de Coimbra, E.P.E., Coimbra · Hospital da Luz, S.A, Lisbon · Hospital CUF Porto S.A., Porto · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto
Registry updated 2026-10-28
NCT06875310
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Trial Treatment · Phase 3 · Mirati Therapeutics Inc.
Instituto Portugues De Oncologia De Coimbra Francisco Gentil E.P.E., Coimbra · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Unidade Local De Saude De Santo Antonio E.P.E., Porto
Registry updated 2026-10-27
2023-509340-10-00
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
Trial Treatment · Phase 3 · OSE Immunotherapeutics
Unidade Local de Saúde de Coimbra, E.P.E., Coimbra · Unidade Local De Saude De Santa Maria E.P.E., Lisbon · Hospital Cuf Descobertas S.A., Lisbon · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Hospital CUF Porto S.A., Porto · Unidade Local de Saúde de Gaia/Espinho, E. P. E, Vila Nova de Gaia
Registry updated 2026-10-23
NCT06561386
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Trial Treatment · Phase 3 · Bristol-Myers Squibb
Unidade Local de Saúde de Coimbra, E.P.E., Coimbra · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto · Unidade Local de Saude de Sao Joao E.P.E., Porto
Registry updated 2026-10-23
NCT06899126
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Trial Treatment · Phase 3 · Daiichi Sankyo
Unidade Local De Saude De Santa Maria E.P.E., Lisbon · Hospital da Luz, S.A, Lisbon · Unidade Local De Saude De Santo Antonio E.P.E., Porto · Hospital CUF Porto S.A., Porto
Registry updated 2026-10-23
NCT07361510
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Trial Treatment · Phase 3 · Bristol-Myers Squibb
CCAB Centro Clinico Academico Braga Associacao, Braga · Unidade Local De Saude De Santa Maria E.P.E., Lisbon
Registry updated 2026-10-23
2024-518348-19-00
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Trial Treatment · Phase 1 · Novartis Pharma AG
Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto
Registry updated 2026-10-21
NCT05061550
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Trial Treatment · Phase 2 · AstraZeneca
Hospital da Luz, S.A, Lisbon · Unidade Local De Saude De Sao Jose E.P.E., Lisbon · Champalimaud Clinical Centre, Lisbon · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto
Registry updated 2026-10-21
NCT05099172
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 1/2 · Bayer
Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto
Registry updated 2026-10-21
NCT07099898
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Trial Treatment · Phase 3 · GlaxoSmithKline
Almada · Coimbra · Guimarães · Lisbon
Registry updated 2026-10-20
NCT06312137
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Instituto Portugues De Oncologia De Coimbra Francisco Gentil E.P.E., Coimbra · Centro Hospitalar Universitario De Lisboa Norte E.P.E., Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto · Unidade Local De Saude De Matosinhos E.P.E., Senhora Da Hora
Registry updated 2026-10-15
NCT07541170
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · Hoffmann-La Roche
Instituto Portugues De Oncologia De Coimbra Francisco Gentil E.P.E., Coimbra · Hospital Cuf Tejo S.A., Lisbon · Champalimaud Clinical Centre, Lisbon · Unidade Local De Saude De Loures-Odivelas EPE, Loures · Unidade Local de Saude de Sao Joao E.P.E., Porto · Unidade Local de Saúde de Gaia/Espinho, E. P. E, Vila Nova de Gaia
Registry updated 2026-10-13
NCT07005102
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Trial Treatment · Phase 2/3 · AbbVie
Unidade Local de Saude de Braga, EPE /ID# 275394, Braga · Unidade Local de Saude de Santo Antonio /ID# 275387, Porto · Hospital Cuf Porto /ID# 275395, Porto
Registry updated 2026-10-05

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error